DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026)

DBV Technologies (DBVT) posted quarterly Total Non-Current Liabilities of $8.5 million for Q2 2026, up 9.25% year-on-year from $7.8 million in Q2 2025, and up 26.87% on a QoQ basis from $6.7 million in Q1 2026.

DBV Technologies (DBVT) Total Non-Current Liabilities (2015 - 2026) Analysis & Trends

DBV Technologies (DBVT) has reported Total Non-Current Liabilities for 12 consecutive years, with $8.5 million the latest figure, recorded in Q2 2026.

  • Quarterly Total Non-Current Liabilities rose 9.25% year-over-year to $8.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.5 million (up 9.25% YoY) and the FY2025 annual result came in at $6.9 million, down 3.29% from the prior year.
  • Total Non-Current Liabilities advanced to $8.5 million in Q2 2026 per DBVT's latest filing, from $6.7 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for DBVT reached as high as $22.5 million in Q4 2022 and fell as low as $5.5 million in Q4 2023.
  • A 5-year average of $10.4 million and a median of $7.9 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • The largest YoY upside for Total Non-Current Liabilities was 121.92% in 2023 against a maximum downside of 75.78% in 2023.
  • Year by year, Total Non-Current Liabilities stood at $22.5 million in 2022, then slumped by 75.78% to $5.5 million in 2023, then soared by 30.65% to $7.1 million in 2024, then retreated by 3.29% to $6.9 million in 2025, then rose by 23.19% to $8.5 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $8.5 million, $6.7 million, and $6.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 DBV Technologies 267.50 Mn 92.60 Mn - 8.50 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 8.50 Mn
Mar 31, 2026 6.70 Mn
Dec 31, 2025 6.90 Mn
Sep 30, 2025 8.16 Mn
Jun 30, 2025 7.78 Mn
Mar 31, 2025 7.31 Mn
Dec 31, 2024 7.14 Mn
Sep 30, 2024 8.11 Mn
Jun 30, 2024 7.71 Mn
Mar 31, 2024 7.76 Mn
Dec 31, 2023 5.46 Mn
Sep 30, 2023 14.35 Mn
Jun 30, 2023 19.91 Mn
Mar 31, 2023 21.06 Mn
Dec 31, 2022 22.54 Mn
Sep 30, 2022 7.67 Mn
Jun 30, 2022 10.13 Mn
Mar 31, 2022 9.49 Mn
Dec 31, 2021 16.05 Mn
Sep 30, 2021 20.22 Mn